Authors
Latest:
Bristol-Myers Squibb Sells Diabetes Business to AstraZenecaBristol-Myers Squibb has agreed to sell its global diabetes business that was part of its collaboration with AstraZeneca for $2.7 billion with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025.
Latest:
Tracking Trial Cost Drivers: The Impact of Comparator Drugs and Co-TherapiesNew research from the Tufts Center for the Study of Drug Development identifies a significant contributor to the rising cost of clinical trials-the first step in meeting a growing strategic imperative to help senior management and the regulatory community craft new approaches to make trials more efficient in delivering results to clinicians and patients.
Latest:
The Truth About E-HealthThe returns are in, and they are not pretty. Janus Funds' billion-dollar investment in WebMD in 2000 now has a net value of roughly ten cents on the dollar, and many observers see WebMD as a winner in their space-whatever that space is now.
Latest:
Medical Affairs: From Info Gatekeeper to Legitimate Value DriverThe role of pharma medical affairs teams is taking on greater importance in the value chain.
Latest:
September 2016: Your Hub is Your Secret Weapon to Improve OutcomesHubs can be the secret weapon to providing customized solutions to the industry-wide challenge of improving patient outcomes.
Latest:
Market Access is Dead: Patient Access is the New Prescription for Healthcare MarketingParadigms change when questions emerge the old paradigm can no longer answer. Market access has become a buzz word as access to markets is as significant a hurdle to product usage as registration itself. I
Latest:
Patients Outcomes Impact (POI™): The Evolution of Measuring Patient-Centered InvestmentMichael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.
Latest:
Promotional Review Committees Shire Sets the Standard on Achieving High Performing TeamsWhat does it take for internal Promotional Review Committees to function at their best and avoid costly mistakes to the company? A leading industry practitioner offers 15 tips for high performing teams.
Latest:
Doctors in the HouseA growing number of physicians are expressing interest in working in the pharmaceutical industry. Many are motivated by the desire to get as far away from managed clinical care as possible. Others want to broaden their sphere of influence in healthcare-to move from treating one patient at a time to helping an entire patient population. Still others are excited by the chance to participate in well funded cutting-edge innovation or are influenced by colleagues who have moved into pharmaceutical medicine and are vocal about their enhanced career satisfaction.
Latest:
Jan van de Winkel: Antibody AscensionJan van de Winkel, PhD, president and CEO of Genmab, the longtime innovation engine in antibody drug development, discusses its vision for adding a new business identity: commercial driver.
Latest:
Strengthen your greatest asset: your voiceThe quality of our voice can say more about us then the words we speak.
Latest:
Outcomes Data: A Critical Insight for Market AccessReal-world pharmacoeconomic data can provide critical insight for maximizing US market access and oncology product differentiation, and should be central to the overall brand strategy of any oncology product
Latest:
Outcomes Data: A Critical Insight for Market AccessReal-world pharmacoeconomic data can provide critical insight for maximizing US market access and oncology product differentiation, and should be central to the overall brand strategy of any oncology product
Latest:
Industry Growth Slowdown in BrazilThe Brazilian economy is being impacted by internal and external factors, and forecast figures are being quickly revised downwards. Market research released by Brazil’s Central Bank revised average analysts’ projections for economic growth in 2014 down to 0.70% from 0.90% four weeks earlier(1).
Latest:
Find a key to the impossible accountSince sales success starts by reaching the decision-maker, sales representatives must find creative ways to penetrate the barriers that surround the toughest accounts.
Latest:
Field of DreamsCancer makes neurology seem almost simple by comparison. Cancers come in a nearly infinite variety. Yet their mechanisms, scientists now surmise, may reside in the same place-deep inside the cell. DNA, genes, and cellular proteins play key roles in both disease areas.
Latest:
Special DeliveryNew drug delivery mechanisms and devices are an opportunity to build relationship with the ultimate customer: the patient.
